



Quest Diagnostics Appoints New Leader at Nichols Institute

July 8, 1997

San Juan Capistrano, CA, July 8, 1997 — David L. Cooper, Ph.D., M.D., an internationally-recognized medical authority in molecular diagnostics and molecular science, has been named Scientific Director and Chief Operating Officer of the Reference Laboratory at Quest Diagnostics' Nichols Institute. In his new role, Dr. Cooper will manage reference laboratory operations for Quest Diagnostics' San Juan Capistrano-based facility, oversee research and development activities, and supervise business administration functions at Nichols Institute.

Quest Diagnostics' Nichols Institute is a global leader in the provision of complex diagnostic, prognostic, and cancer detection marker testing for hospitals, independent laboratories and physicians. These tests incorporated the latest scientific and medical advances in molecular diagnostics, including polymerase chain reaction (PCR) Amplification and DNA Probe Analysis technologies to substantiate diagnosis and monitor effectiveness of treatment.

Dr. Cooper has more than twenty years of experience in molecular biology and genetics, and over a decade of experience in clinical service. Most recently he was Associate Professor of Pathology at the University of Pittsburgh and Associate Member of the Pittsburgh Cancer Institute. He has held numerous academic and medical appointments, including servings as Assistant Professor of Pathology at Duke University Medical Center, Durham, North Carolina. Dr. Cooper completed post-doctoral fellowships at Johns Hopkins University, Baltimore, Maryland, and the Institute for Cancer Research/Fox Chase, Philadelphia, Pennsylvania.

"Dr. Cooper's expertise and leadership in the field of molecular diagnostics squarely position Nichols Institute as Quest Diagnostics' Center for Diagnostic Innovation," said Gregory Critchfield, M.D., Senior Vice President and Chief Medical and Science Officer for Quest Diagnostics. "This signals our commitment to the growth of molecular medicine in health care, and the provision of the most technologically-advanced diagnostic and prognostic testing services in a commercial reference laboratory environment.

Formerly the president of the Association for Molecular Pathology, Dr. Cooper is currently Editor-in-Chief for the scientific journal *Molecular Diagnosis*. He also holds the distinction of being one of four Americans to serve on the International Editorial Advisory Board for the *Journal of Pathology*. He won a Physiology Fellowship at the Marine biology Laboratory, Woods Hole, Massachusetts and held The Lichfield Lectureship, Nuffield Department of Pathology & Bacteriology at Oxford University, Headington, Oxford, England.

Dr. Cooper is internationally known in the field of molecular biology and medicine. He has been funded by research grants from the National Institutes of Health, The American Cancer Society, and the Department of Defense in the areas of gene diagnostics and therapeutics. He holds a Ph.D. in Chemistry from Florida State University, Tallahassee, Florida and a M.D. in Medicine from the University of Florida, Gainesville, Florida. He completed his Internship in pediatrics in 1985 and served his Clinical Pathology Residency at the University of Florida in 1987.

Quest Diagnostics Incorporated is one of the world's leading providers of diagnostic testing, information and services, with regional laboratories across the United States. The wide variety of tests performed on human tissue and fluids help doctors and hospitals diagnose, treat and monitor disease. Quest Diagnostics' Nichols Institute conducts research, produces test kits and instruments, and specializes in esoteric testing using genetic screening and other advanced technologies. Formerly known as Corning Clinical Laboratories Inc., Quest Diagnostics was spun off to Corning Incorporated stockholders in a tax-free distribution of shares on December 31, 1996.